Evidence map›Paper›PMID 26732803›Full record

ArticleParkinsonism & related disorders2016

The V81M variant of tyrosine hydroxylase is associated with more severe freezing of gait in Parkinson's disease.

Izel Tekin, Nurgul Carkaci-Salli, Mechelle M Lewis, Richard B Mailman, Xuemei Huang, Kent E Vrana

Abstract read
In one paragraph

Article in Parkinsonism & related disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Freezing of gait: overview on etiology, treatment, and future directions.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Izel TekinDepartment of Pharmacology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA.
Nurgul Carkaci-SalliDepartment of Pharmacology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA.
Mechelle M LewisDepartment of Pharmacology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Neurology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA.
Richard B MailmanDepartment of Pharmacology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Neurology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA.
Xuemei HuangDepartment of Pharmacology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA; Department of Neurology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA; Departments of Radiology and Neurosurgery, Milton S. Hershey Medical Center, and Kinesiology, Pennsylvania State University, Hershey, PA, USA.
Kent E VranaDepartment of Pharmacology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: kvrana@psu.edu.
Pennsylvania State University · USPenn State Milton S. Hershey Medical Center · US

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Penn State Clinical and Translational Science InstituteUL1TR000127 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2012 to 2015
$17.1M
Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's DiseaseU01NS082151 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI · 2012 to 2016
$4.2M
Structural MRI marker(s) of Parkinson's Disease's ProgressionR01NS060722 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI HUANG, XUEMEI · 2009 to 2013
$2.9M
MOLECULAR CHARACTERIZATION OF TYROSINE HYDEOXYLASER01GM038931 · NIGMS · WEST VIRGINIA UNIVERSITY · PI VRANA, KENT E · 1991 to 2010
$2.0M
GCRC RELOCATION AND EXPANSION PROJECTC06RR016499 · NCRR · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KIRCH, DARRELL G · 2001 to 2001
$707k
Penn State Clinical and Translational Science InstituteTL1TR000125 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2012 to 2015
$550k
NCATS NIH HHS NIH UL1 TR000127NCATS NIH HHS TL1 TR000125NCATS NIH HHS UL1 TR000127NCATS NIH HHS UL1 TR002014NCRR NIH HHS C06 RR016499NCRR NIH HHS C06RR016499NIGMS NIH HHS GM38931NIGMS NIH HHS R01 GM038931NINDS NIH HHS NIH NS060722NINDS NIH HHS NS082151NINDS NIH HHS R01 NS060722NINDS NIH HHS U01 NS082151
6 · The paper itself

Abstract

introductionMany of the symptoms and signs of Parkinson's disease (PD) arise from the death of midbrain dopamine neurons that utilize tyrosine hydroxylase (TH) as the rate-limiting enzyme in catecholamine biosynthesis.

methodsWe investigated whether the presence of a common TH polymorphism affects the clinical outcomes in 101 PD subjects. We further examined the effect of this polymorphism on the purified recombinant enzyme.

resultsPD subjects homozygous for the common V81M polymorphism, have higher overall freezing of gait scores after controlling for disease duration, although this polymorphism does not associate with the occurrence of PD or FOG. In vitro functional assays on pure recombinant wild type TH and V81M TH revealed that the Km of the mutant enzyme for tyrosine was twice that of the wild-type. This polymorphism, however, did not change the stability of the enzyme, nor did it affect the Vmax or Km for the co-substrate BH4.

conclusionThe data suggest that presence of a homozygous V81M polymorphism is associated with more severe FOG, possibly due to lower catecholamine synthetic capacity. Further studies are warranted to investigate the role of subtle changes in catecholamine availability in the development of FOG.

Indexed as

AgedDNA Mutational AnalysisFemaleGait Disorders, NeurologicHumansMaleMiddle AgedMutagenesis, Site-DirectedParkinson DiseasePolymorphism, Single NucleotideTyrosine 3-MonooxygenaseTyrosine 3-MonooxygenaseDopamineMovement disordersNorepinephrinePolymorphismSNP

Identifiers

PMID26732803
PMCPMC4770791
OpenAlexW2219131824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.